Updates in the Management of Myeloproliferative Neoplasms

EP. 1: Characterization of Myeloproliferative Neoplasms

July 7th 2020

EP. 2: Polycythemia Vera: Diagnostic Work-up

July 7th 2020

EP. 3: Polycythemia Vera: Bone Marrow Biopsies

July 7th 2020

EP. 4: Polycythemia Vera: Prognostic Markers

July 7th 2020

EP. 5: Polycythemia Vera: Risk Assessment

July 7th 2020

EP. 6: Polycythemia Vera: Monitoring Patients

July 7th 2020

EP. 7: Management of Low-Risk Polycythemia Vera

July 7th 2020

EP. 8: Treatment Options for High-Risk Polycythemia Vera

July 7th 2020

EP. 9: Polycythemia Vera: Switching Therapy

July 7th 2020

EP. 10: Polycythemia Vera: Ruxolitinib Trial Data

July 7th 2020

EP. 11: Utilization of Ruxolitinib for Polycythemia Vera

July 7th 2020

EP. 12: Polycythemia Vera: PROUD-PV Trial

July 7th 2020

EP. 13: Primary Myelofibrosis: Risk Stratification

July 7th 2020

EP. 14: Management of Low-Risk Primary Myelofibrosis

July 7th 2020

EP. 15: Treating Intermediate/High-Risk Primary Myelofibrosis

July 7th 2020

EP. 16: Ruxolitinib for Primary Myelofibrosis

July 7th 2020

EP. 17: Ruxolitinib and Surgical Interventions

July 7th 2020

EP. 18: Fedratinib for Primary Myelofibrosis

July 7th 2020

EP. 19: JAK2 Inhibitor Selection for Primary Myelofibrosis

July 7th 2020

EP. 20: Primary Myelofibrosis: Trials of Interest

July 7th 2020

NEXT PAGE
PREVIOUS PAGE